KIT W557_K558DELWK (Q29938433)

From Wikidata

Jump to navigation Jump to search

genetic variant

W557_K558DELWK

Language	Label	Description	Also known as
English	KIT W557_K558DELWK	genetic variant	W557_K558DELWK

Statements

sequence variant

1 reference

12 July 2017

https://civic.genome.wustl.edu/links/variants/961

human chromosome 4

genomic assembly

Genome assembly GRCh37

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/variants/961

55593603

genomic assembly

Genome assembly GRCh37

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/variants/961

55593608

genomic assembly

Genome assembly GRCh37

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/variants/961

biological variant of

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/variants/961

positive therapeutic predictor for

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/4084

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/4084

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/4087

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/4087

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

statement disputed by

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/2481

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/evidence/4082

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Identifiers

CIViC variant ID

1 reference

28 August 2020

https://civic.genome.wustl.edu/links/variants/961

dbSNP Reference SNP number

1 reference

HGVS nomenclature

chr4:g.55593603_55593608del

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938433&oldid=2014804528"